Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases

Slides:

Advertisements

Similar presentations

Irritable Bowel Syndrome and Microscopic Colitis: A Systematic Review and Meta- analysis Eline J.C.A. Kamp, John S. Kane, Alexander C. Ford Clinical Gastroenterology.

Advertisements

Long-term Follow-up Reveals Low Incidence of Colorectal Cancer, but Frequent Need for Resection, Among Australian Patients With Inflammatory Bowel Disease.

MiraLAX Is Not as Effective as GoLytely in Bowel Cleansing Before Screening Colonoscopies Michael Hjelkrem, Joel Stengel, Mark Liu, David P. Jones, Stephen.

Risk of Neoplasia After Colectomy in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis Lauranne A.A.P. Derikx, Loes H.C.

Travel-Associated Health Risks for Patients With Inflammatory Bowel Disease Shomron Ben–Horin, Yoram Bujanover, Shulamit Goldstein, Moshe Nadler, Alon.

Saurabh Dawra, Vishal Sharma, Usha Dutta

Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to- Moderate Ulcerative Colitis in a Randomized Controlled Trial Alon.

Issue Highlights Clinical Gastroenterology and Hepatology

Flavia D. Mendes, Ayako Suzuki, Schuyler O. Sanderson, Keith D

Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation Shomron Ben-Horin, Niels Vande Casteele, Stefan Schreiber, Peter Laszlo Lakatos

Prevalence, Characteristics, and Impact of Bloating Symptoms in Patients With Irritable Bowel Syndrome Yehuda Ringel, Rachel E. Williams, Linda Kalilani,

Nitsan Maharshak, Scott E. Plevy

Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases Bella Ungar, Uri.

Pichamol Jirapinyo, Christopher C. Thompson

Gauree Gupta, Ebbing Lautenbach, James D. Lewis

A Shocking Cystory Clinical Gastroenterology and Hepatology

Immune Reconstitution Inflammatory Syndrome of the Small Bowel in a Human Immunodeficiency Virus–Negative Patient Severin Daum, Christoph Loddenkemper,

Prevalence of Irritable Bowel Syndrome–type Symptoms in Patients With Celiac Disease: A Meta-analysis Anita Sainsbury, David S. Sanders, Alexander C.

Liver Cirrhosis Is Associated With Venous Thromboembolism Among Hospitalized Patients in a Nationwide US Study Harry Wu, Geoffrey C. Nguyen Clinical.

Patient-Reported Outcome Measures for Use in Clinical Trials and Clinical Practice in Inflammatory Bowel Diseases: A Systematic Review Marin J. de Jong,

Effects of Combination Therapy With Immunomodulators on Trough Levels and Antibodies Against Tumor Necrosis Factor Antagonists in Patients With Inflammatory.

Stephen A. Harrison, MD, FACP Clinical Gastroenterology and Hepatology

Many Patients With Primary Sclerosing Cholangitis and Increased Serum Levels of Carbohydrate Antigen 19-9 Do Not Have Cholangiocarcinoma Emmanouil Sinakos,

Ability of King's College Criteria and Model for End-Stage Liver Disease Scores to Predict Mortality of Patients With Acute Liver Failure: A Meta-analysis

Personalizing Colorectal Cancer Screening: A Systematic Review of Models to Predict Risk of Colorectal Neoplasia Gene K. Ma, Uri Ladabaum Clinical Gastroenterology.

Clinical Features, Treatment, and Survival of Patients With Colorectal Cancer With or Without Inflammatory Bowel Disease Raja Affendi Raja Ali, Cara.

Miguel Regueiro, Kevin E. Kip, Leonard Baidoo, Jason M

Activity-Based Costing and Management in a Hospital-Based GI Unit

Risk of Nonmelanoma Skin Cancer in Patients With Inflammatory Bowel Disease Who Use Thiopurines Is Not Increased Fiona D.M. van Schaik, Martijn G.H.

Michael Hjelkrem, Joel Stengel, Mark Liu, David P. Jones, Stephen A

Endoscopic Therapy for Barrett's Esophagus

Traveling Internationally: Avoiding and Treating Travelers' Diarrhea

AGA Clinical Practice Update on Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: Expert Review Jean-Frederic Colombel,

Millie D. Long, Hans H. Herfarth, Clare A. Pipkin, Carol Q

Leon P. McLean, Jonathan S. Chun, Raymond K. Cross

Mild Enteropathy Celiac Disease: A Wolf in Sheep's Clothing?

Low Serum Vitamin D During Remission Increases Risk of Clinical Relapse in Patients With Ulcerative Colitis John Gubatan, Shuji Mitsuhashi, Talia Zenlea,

Bara Erhayiem, Rajpal Dhingsa, Christopher J

Reenu Malhotra, Kevin Turner, Amnon Sonnenberg, Robert M. Genta

Endoscopic Ultrasound–Guided Cholecystoduodenostomy for Acute Cholecystitis in a Patient With Thrombocytopenia and End-Stage Liver Disease Awaiting Transplantation

David H. Bruining, William J. Sandborn

Rebecca M. Lovell, Alexander C. Ford

Mucosal Healing Is Associated With Improved Long-term Outcomes of Patients With Ulcerative Colitis: A Systematic Review and Meta-analysis Shailja C.

Association Between Pharmacokinetics of Adalimumab and Mucosal Healing in Patients With Inflammatory Bowel Diseases Xavier Roblin, Hubert Marotte, Melanie.

Addition of an Immunomodulator to Infliximab Therapy Eliminates Antidrug Antibodies in Serum and Restores Clinical Response of Patients With Inflammatory.

Early Trough Levels and Antibodies to Infliximab Predict Safety and Success of Reinitiation of Infliximab Therapy Filip Baert, David Drobne, Ann Gils,

Effects of Different Coping Strategies on Physical and Mental Health of Patients With Irritable Bowel Syndrome Lilian Dindo, PhD Clinical Gastroenterology.

Risk of Cerebrovascular Accidents and Ischemic Heart Disease in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis Siddharth.

Issue Highlights Clinical Gastroenterology and Hepatology

Issue Highlights Clinical Gastroenterology and Hepatology

Elizabeth Mileti, Philip Rosenthal, Marion G. Peters

Ethnicity Influences Phenotype and Outcomes in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis of Population-based Studies Hai Yun.

Correlation Between the Crohn's Disease Activity and Harvey–Bradshaw Indices in Assessing Crohn's Disease Severity Severine Vermeire, Stefan Schreiber,

Endoscopic Ultrasound and Endoscopic Mucosal Resection Features of a Non–Protein Losing Form of Ménétrier's Disease Ferga C. Gleeson, Thomas F. Mangan,

Nicolas Williet, William J. Sandborn, Laurent Peyrin–Biroulet

Javier Oliver, Blanca Rueda, Miguel A

Temporal Trends in Initiation of Therapy With Tumor Necrosis Factor Antagonists for Patients With Inflammatory Bowel Disease: A Population-based Analysis

Walter Reinisch, Jean-Frederic Colombel, William J

Meenakshi Bewtra, Chinyu Su, James D. Lewis

Coagulation in Liver Disease: A Guide for the Clinician

Endoscopic Assessment and Treating to Target Increase the Likelihood of Mucosal Healing in Patients With Crohn’s Disease Guillaume Bouguen, Barrett G.

Endoscopic Therapy of Jejunal Diphyllobothrium nihonkaiense Infection

Risk of Pancreatitis in Patients With Celiac Disease: Is Autoimmune Pancreatitis a Biologically Plausible Mechanism? John S. Leeds, David S. Sanders

Coloduodenal Fistula in Crohn’s Disease

Rintaro Hashimoto, Akimichi Chonan

Adverse Outcomes: Why Bad Things Happen to Good People

Medical Therapy for Refractory Pediatric Crohn’s Disease

Rintaro Hashimoto, Akimichi Chonan

Klaus Mönkemüller, Helmut Neumann, Lucia C. Fry

Jordan E. Axelrad, Sharyle A. Fowler, Sonia Friedman, Ashwin N

Presentation transcript:

Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases Bella Ungar, Idan Levy, Yarden Yavne, Miri Yavzori, Orit Picard, Ella Fudim, Ronen Loebstein, Yehuda Chowers, Rami Eliakim, Uri Kopylov, Shomron Ben-Horin Clinical Gastroenterology and Hepatology Volume 14, Issue 4, Pages 550-557.e2 (April 2016) DOI: 10.1016/j.cgh.2015.10.025 Copyright © 2016 AGA Institute Terms and Conditions

Figure 1 (A) Infliximab trough levels in patients with MH versus those with endoscopically active disease (no MH). (B) ROC analysis, correlation between infliximab levels and MH. AUC, area under the curve. Clinical Gastroenterology and Hepatology 2016 14, 550-557.e2DOI: (10.1016/j.cgh.2015.10.025) Copyright © 2016 AGA Institute Terms and Conditions

Figure 2 The correlation between ATI levels and MH among patients with satisfactory infliximab levels. Clinical Gastroenterology and Hepatology 2016 14, 550-557.e2DOI: (10.1016/j.cgh.2015.10.025) Copyright © 2016 AGA Institute Terms and Conditions

Figure 3 (A) Adalimumab trough levels in patients with MH versus those with endoscopically active disease (no MH). (B) ROC analysis, correlation between adalimumab levels and MH. AUC, area under the curve. Clinical Gastroenterology and Hepatology 2016 14, 550-557.e2DOI: (10.1016/j.cgh.2015.10.025) Copyright © 2016 AGA Institute Terms and Conditions

Figure 4 Incremental gain in MH rates in relation to drug serum level. Clinical Gastroenterology and Hepatology 2016 14, 550-557.e2DOI: (10.1016/j.cgh.2015.10.025) Copyright © 2016 AGA Institute Terms and Conditions

Supplementary Figure 1 Drug level in relation to endoscopic score in 2 patients with CD. SES for CD score <3 signifies MH (dashed line). Squares, infliximab therapy patient; circles, adalimumab therapy patient; SES, Simple Endoscopic Score. Clinical Gastroenterology and Hepatology 2016 14, 550-557.e2DOI: (10.1016/j.cgh.2015.10.025) Copyright © 2016 AGA Institute Terms and Conditions